CogniCurrent Icon

COGNICURRENT

A compact global news feed for the bigger picture.

βŒ•
Regions
Topics
Saved views:
Save your current filters to revisit or share.
5 stories
πŸ‡¦πŸ‡· Clarin (ES)
National & Local

The dreaded rebound effect: only 4 out of every 10 people lose weight without regaining it

A report reveals that a significant percentage of Spaniards attempt weight loss, often without medical support, and many resort to popular diets.

Feb 10 β€’ 10:30 UTC
πŸ‡ͺπŸ‡Έ ABC
Life & Tech

More than 1 in 4 adults could benefit from new anti-obesity drugs

A study suggests implementing strategic programs for GLP-1 medications to address the global obesity crisis, while also warning about the rebound effect of drugs like Ozempic.

Jan 8 β€’ 23:32 UTC
πŸ‡ͺπŸ‡Έ ABC
Life & Tech

The rebound effect of Ozempic-type drugs: patients regain weight in less than two years

A meta-analysis of 37 studies warns that after discontinuing medications like Ozempic, patients tend to regain weight and return to prior cardiovascular and metabolic risk levels in less than two years.

Jan 8 β€’ 10:55 UTC
πŸ‡ͺπŸ‡Έ El Mundo
Life & Tech

Abandoning Ozempic family drugs: the rebound effect that also recovers hypertension and cholesterol

The article discusses the rebound effects experienced by patients who discontinue Ozempic family drugs, highlighting the loss of cardiovascular health benefits such as controlled blood pressure and low cholesterol levels.

Jan 7 β€’ 23:30 UTC
πŸ‡ͺπŸ‡Έ El PaΓ­s
Life & Tech

The trap of 'miracle' weight loss medications: the rebound effect is faster than with conventional diets

A study of 37 investigations reveals that the rebound weight gain from GLP-1 agonists happens in less than two years, highlighting the hidden downsides of these popular obesity therapies.

Jan 7 β€’ 23:30 UTC

Story in context

Loading Intelligence...

πŸ“‘

Select a report from the feed to view analysis and related coverage.